A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
NCT ID: NCT00189813
Last Updated: 2014-08-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
691 participants
INTERVENTIONAL
2005-03-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
NCT00189696
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
NCT01870895
A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome
NCT01736423
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
NCT01274000
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
NCT00918411
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YM060
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient reported having any Type 1 or Type 2 stool on the Bristol Stool Form Scale during the run-in period
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe B.V.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
F. Verbeeck
Role: STUDY_CHAIR
Director of Late Phase Development
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Varna, , Bulgaria
České Budějovice, , Czechia
Hradec Králové, , Czechia
Ostrava Hrabuvka, , Czechia
Prague, , Czechia
Tábor, , Czechia
Ústí nad Orlicí, , Czechia
Tallinn, , Estonia
Tartu, , Estonia
Viljandi, , Estonia
Berlin, , Germany
Bochum, , Germany
Dietzenbach, , Germany
Essen, , Germany
Frankfurt, , Germany
Friedberg, , Germany
Hamburg, , Germany
Haßloch, , Germany
Königstein, , Germany
Leipzig, , Germany
Mainz, , Germany
Marburg, , Germany
Potsdam, , Germany
Waltershausen, , Germany
Kaunas, , Lithuania
Klaipėda, , Lithuania
Vilnius, , Lithuania
Bialystok, , Poland
Bydgoszcz, , Poland
Krakow, , Poland
Leszno, , Poland
Lublin, , Poland
Oława, , Poland
Warsaw, , Poland
Moscow, , Russia
Saint Petersburg, , Russia
Yaroslavl, , Russia
Dnipropetrovsk, , Ukraine
Kiev, , Ukraine
Lviv, , Ukraine
Odesa, , Ukraine
Simferopol, , Ukraine
Sumy, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
060-CL-305
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.